Iñiguez-Ariza Nicole M, Brito Juan P
Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
Endocrinol Metab (Seoul). 2018 Jun;33(2):185-194. doi: 10.3803/EnM.2018.33.2.185.
The incidence of thyroid cancer has increased, mainly due to the incidental finding of low-risk papillary thyroid cancers (PTC). These malignancies grow slowly, and are unlikely to cause morbidity and mortality. New understanding about the prognosis of tumor features has led to reclassification of many tumors within the low-risk thyroid category, and to the development of a new one "very low-risk tumors." Alternative less aggressive approaches to therapy are now available including active surveillance and minimally invasive interventions. In this narrative review, we have summarized the available evidence for the management of low-risk PTC.
甲状腺癌的发病率有所上升，主要是由于偶然发现了低风险的甲状腺乳头状癌（PTC）。这些恶性肿瘤生长缓慢，不太可能导致发病和死亡。对肿瘤特征预后的新认识导致了低风险甲状腺类别中许多肿瘤的重新分类，并产生了一个新的类别“极低风险肿瘤”。现在有了其他侵袭性较小的治疗方法，包括主动监测和微创干预。在这篇叙述性综述中，我们总结了低风险PTC管理的现有证据。
